Litcius/Paper detail

Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma

Ana Arance, Miguel‐Ángel Berciano‐Guerrero, Jun Guo, M.S. Carlino, Paolo A. Ascierto, Mauricio Burotto, Laurent Mortier, P. Queirolo, Vanna Chiarion‐Sileni, Jacob Schachter, Xiang Zhang, J. Martin-Liberal, M. Del Vecchio, Chinyere E. Okpara, Corina E. Dutcus, Jie Zhang, Scott J. Diede, Tobias Neff, Georgina V. Long

2025Annals of Oncology7 citationsDOI

Topics & Concepts

PembrolizumabMedicineLenvatinibPlaceboOncologyInternal medicineDouble blindPhases of clinical researchMetastatic melanomaImmunotherapyClinical trialCancerPathologyThyroid cancerAlternative medicineCancer Immunotherapy and BiomarkersMelanoma and MAPK PathwaysCAR-T cell therapy research
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma | Litcius